Prevalence of chronic kidney diseases in patients with chronic obstructive pulmonary disease: assessment based on glomerular filtration rate estimated from creatinine and cystatin C levels

Takayuki Yoshizawa1,2, Kazuyoshi Okada3, Sachiko Furuiuchi1,2, Toshihiko Ishiguro1, Akitaka Yoshizawa1, Toshihi Akahoshi2, Yasuhiro Gon2, Tsuneto Akashiba2, Yoshifumi Hosokawa1,2, Shu Hashimoto2

1Department of Internal Medicine, Kanamecho Hospital, Toshima-ku, Tokyo, Japan; 2Department of Internal Medicine, Toshima-ku, Tokyo, Japan; 3Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan

Background: Cardiovascular diseases, osteoporosis, and depression are identified comorbidities of chronic obstructive pulmonary disease (COPD), but there have been few reports of chronic kidney disease (CKD) as a comorbidity of COPD. The objective of this study was to investigate the prevalence of CKD in COPD patients using estimated glomerular filtration rate (eGFR) based on creatinine (Cr) and cystatin C (Cys) levels.

Methods: The prevalence of CKD and the values of various CKD-related parameters were compared between 108 stable COPD outpatients (COPD group) and a non-COPD control group consisting of 73 patients aged 60 years or more without a history of COPD or kidney disease. CKD was defined as an eGFR less than 60 mL/min/1.73 m².

Results: The Cr level was significantly higher in the COPD group, but eGFR based on serum Cr (eGFRcr) was not significantly different between the two groups (73.3±25.3 vs 79.7±15.5 mL/min/1.73 m²). The Cys level was significantly higher and eGFR based on serum Cys (eGFRcys) was significantly lower in the COPD group (60.0±19.4 vs 74.0±13.5 mL/min/1.73 m², P<0.0001). The prevalence of CKD evaluated based on eGFRcr was 31% in the COPD group and 8% in the non-COPD group with an odds ratio of 4.91 (95% confidence interval, 1.94–12.46, P=0.0008), whereas the evaluated prevalence based on eGFRcys was 53% in the COPD group and 15% in the non-COPD group with an odds ratio of 6.30 (95% confidence interval, 2.99–13.26, P<0.0001), demonstrating a higher prevalence of CKD when based on eGFRcys rather than on eGFRcr.

Conclusion: CKD is a comorbidity that occurs frequently in COPD patients, and we believe that renal function in Japanese COPD patients should preferably be evaluated based not only on Cr but on Cys in combination with Cys.

Keywords: CKD, comorbidity, COPD, eGFR

Introduction

Chronic obstructive pulmonary disease (COPD) is a systemic disease with various comorbidities and is associated with underlying systemic inflammation.1-3 Because the comorbidities of COPD affect disease severity and prognosis, the screening and treatment of comorbidities are key to the control of COPD.4,5 Cardiovascular diseases (CVD), osteoporosis, and depression are considered to be representative comorbidities of COPD,6 but chronic kidney disease (CKD) has been minimally investigated in this context. Advanced age and smoking as well as COPD are risk factors for CKD, which is also known to be an important risk factor for CVD.7-10 A recent report that a high rate of microalbuminuria was detected in COPD patients has focused attention on the correlation between COPD and CKD. It has also been pointed...
out that CKD may be missed if, in elderly COPD patients with decreased muscle mass, the diagnosis is based on creatinine (Cr) levels alone.\textsuperscript{11–16} Cystatin C (Cys) has attracted attention as a biomarker that reflects early renal dysfunction,\textsuperscript{17–21} and a formula to determine the estimated glomerular filtration rate (eGFR) based on Cys levels has been proposed in addition to the conventional estimation formula based on Cr levels.\textsuperscript{22,23} The Japanese Society of Nephrology adopted this new estimation formula in 2012.\textsuperscript{24,25} In this study, we measured both serum Cr and serum Cys levels to investigate the prevalence of CKD in COPD patients from the perspective of renal function.

**Subjects and methods**

In this study, 108 stable COPD outpatients who visited our hospital between May 2011 and April 2012 were compared with a non-COPD control group consisting of 73 outpatients (who visited our hospital during the same period) aged 60 years or more who did not have a history of COPD or kidney disease (Figure 1). Written informed consent was obtained from all subjects of this study. Levels of hemoglobin, blood urea nitrogen, Cr, Cys, and brain natriuretic peptide were evaluated. CKD was defined as an eGFR of less than 60 mL/min/1.73 m\textsuperscript{2}. COPD was diagnosed based on spirometry when the FEV\textsubscript{1}/FVC was less than 70\% after inhalation of a bronchodilator, and the severity of airflow obstruction was judged according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.\textsuperscript{8} eGFR was calculated based on serum Cr and serum Cys levels using the following estimation formulas adopted by the Japanese Society of Nephrology in 2012:

- eGFR based on serum Cr (eGFR\textsubscript{Cr}) level:
  - Men: $194 \times \text{Cr}^{-1.094} \times \text{Age}^{-0.287}$ (mL/min/1.73 m\textsuperscript{2}) \textsuperscript{(1)}
  - Women: $194 \times \text{Cr}^{-1.094} \times \text{Age}^{-0.287} \times 0.739$ (mL/min/1.73 m\textsuperscript{2}) \textsuperscript{(2)}

- eGFR based on serum Cys (eGFR\textsubscript{Cys}) level:
  - Men: $(104 \times \text{Cys}^{-1.019} \times 0.996^{\text{Age}}) - 8$ (mL/min/1.73 m\textsuperscript{2}) \textsuperscript{(3)}
  - Women: $(104 \times \text{Cys}^{-1.019} \times 0.996^{\text{Age}} \times 0.929) - 8$ (mL/min/1.73 m\textsuperscript{2}) \textsuperscript{(4)}

For statistical analyses, the t-test and Fisher’s exact test were used as intergroup tests, and the correlation between the prevalence of CKD and the severity of airflow obstruction was tested using the Cochran–Armitage trend test. The odds ratio between the COPD group and the non-COPD group was calculated with regard to the prevalence of CKD. A P-value of <0.05 was considered statistically significant. This study was approved by the Ethics Committee of the Kanamecho Hospital (approval number 1110). The study was registered with the following registration identification: R000017166 on August 10, 2014.

**Results**

Patient characteristics are summarized in Table 1. The COPD group had significantly higher mean age (74.3±7.1 [COPD] vs 71.8±7.3 [non-COPD] years, \(P=0.0214\)), more male patients (\(P<0.0001\)), and a longer smoking history (\(P<0.0001\)) than the non-COPD group. Body-mass index (BMI) was significantly lower in the COPD group (21.1±3.1 vs 23.7±2.4 kg/m\textsuperscript{2}, \(P<0.0001\)). Regarding comorbidities, the prevalence of hypertension, diabetes mellitus, and dyslipidemia were significantly higher in the non-COPD group, but the prevalence of CVD and bronchial asthma were significantly higher in the COPD group. Biochemical testing indicated significantly higher levels of blood urea nitrogen, Cr, Cys, and brain natriuretic peptide in the COPD group (Table 2). The eGFR did not significantly differ between the two groups when estimated using the formula based on serum Cr (eGFR\textsubscript{Cr}, 73.3±25.3 vs 79.7±15.5 mL/min/1.73 m\textsuperscript{2}), but the eGFR was significantly lower in the COPD group when estimated using the formula based on serum Cys (eGFR\textsubscript{Cys}, 60.0±19.4 vs 74.0±13.5 mL/min/1.73 m\textsuperscript{2}, \(P<0.0001\)). The prevalence of CKD, which was defined as an eGFR less than 60 mL/min/1.73 m\textsuperscript{2}, was 31\% (33 of 108 patients) in the COPD group and 8\% (six of 73 patients) in the non-COPD group (see Table 3) when evaluated with eGFR\textsubscript{Cr}, indicating a significantly higher prevalence of CKD in the COPD group (\(P=0.0004\)) with an odds ratio of 4.91 (95\% confidence interval, 1.94–12.46, \(P=0.0008\)). When evaluated with eGFR\textsubscript{Cys}, the prevalence of CKD was 53\% (57 of 108 patients) in the COPD group and 15\% (eleven of 73 patients) in the non-COPD group, indicating a significantly higher prevalence in the COPD group (\(P<0.0001\)) with an odds ratio of 6.30 (95\% confidence interval, 2.99–13.26, \(P<0.0001\)). Note that the prevalence evaluated with eGFR\textsubscript{Cys} was higher than that evaluated with eGFR\textsubscript{Cr}. No significant correlation was found between the severity of airflow obstruction and the prevalence of CKD in the COPD group (Table 4).

**Discussion**

CKD, a concept that includes all chronic kidney damage or dysfunction, regardless of the primary disease, was proposed by the National Kidney Foundation in the USA in 2002. CKD is defined as the persistence of a decline in renal function to a glomerular filtration rate (GFR) less than 60 mL/min/1.73 m\textsuperscript{2} or findings that suggest renal impairment (eg, proteinuria) for
3 months or more. It has been reported that the prognosis of CKD depends on the primary disease and that CKD is an important risk factor for CVD.26

CKD has risk factors in common with COPD, such as smoking and advanced age, and it has been pointed out that CKD is associated with underlying chronic inflammation. In addition, CKD has many characteristics in common with COPD, such as dependence of patient prognosis on CVD as a comorbidity. Although CKD has not attracted much attention as a comorbidity of COPD, there have recently been several reports showing that chronic renal failure (CRF) and microalbuminuria occur at a high rate in COPD patients, suggesting a correlation between COPD and CKD.11–16

Past studies have evaluated CKD based on Cr levels and microalbuminuria, but no study to date has evaluated CKD based on Cys. Whereas Cr is a byproduct of muscle metabolism, Cys is a low-molecular-weight protein secreted from nucleated cells throughout the body. Cys is filtered by the renal glomeruli without forming complexes and is mostly reabsorbed and metabolized in the renal proximal tubule. Serum Cys concentration is known to increase as a reflection of early renal impairment, and thus Cys has
Yoshizawa et al

attracted attention as an intrinsic marker for the detection of early renal impairment; this approach has the advantage that Cys levels are not affected by muscle mass.17–21 The Japanese Society of Nephrology recommends eGFR_{Cys} over eGFR_{Cr} as an index reflecting the early reduction of renal function in patients with low muscle mass.

In the present study, eGFR did not differ between the COPD group and the non-COPD group when using the estimation formula based on serum Cr (eGFR_{Cr}), but the COPD group had significantly reduced eGFR when the estimation formula based on serum Cys (eGFR_{Cys}) was used. The prevalence of CKD was 31% in the COPD group when evaluated

Table 1 Patient characteristics

| Characteristics                  | COPD patient group (n=108) | Non-COPD patient group (n=73) | P-value |
|----------------------------------|---------------------------|-------------------------------|---------|
| Age, years                       | 74.3±7.1                  | 71.8±7.3                      | 0.0214  |
| Sex, males                       | 90 (83.3)                 | 36 (49.3)                     | <0.0001 |
| BMI, kg/m²                       | 21.1±3.1                  | 23.7±2.4                      | <0.0001 |
| Smoking history                  |                           |                               |         |
| Nonsmoker                        | 0 (0)                     | 30 (41.1)                     |         |
| Past smoker                      | 100 (92.6)                | 36 (49.3)                     |         |
| Current smoker                   | 8 (7.4)                   | 7 (9.6)                       |         |
| Pulmonary function               |                           |                               |         |
| VC, % predicted                  | 88.6±20.3                 | 52.4±21.2                     |         |
| FEV_{1}, % predicted             |                           |                               |         |
| GOLD classification              |                           |                               |         |
| 1                                | 10 (9)                    |                               |         |
| 2                                | 37 (34)                   |                               |         |
| 3                                | 27 (25)                   |                               |         |
| 4                                | 34 (32)                   |                               |         |
| Comorbidities and underlying diseases |                       |                               |         |
| Hypertension                     | 50 (46.3)                 | 48 (65.8)                     | 0.0147  |
| Diabetes mellitus                | 14 (13.0)                 | 26 (35.6)                     | 0.0005  |
| Dyslipidemia                     | 14 (13.0)                 | 39 (53.4)                     | <0.0001 |
| Cardiovascular diseases          | 45 (41.7)                 | 15 (20.5)                     | 0.0037  |
| Liver diseases                   | 7 (6.5)                   | 3 (2.7)                       | NS      |
| Gastrointestinal diseases        | 27 (25.0)                 | 15 (20.5)                     | NS      |
| Osteoporosis                     | 28 (25.9)                 | 10 (13.7)                     | NS      |
| Depression                       | 6 (5.6)                   | 2 (2.7)                       | NS      |
| Sleep apnea syndrome             | 2 (1.9)                   | 3 (4.1)                       | NS      |
| Bronchial asthma                 | 23 (21.3)                 | 3 (4.1)                       | 0.001   |
| Malignant tumor                  | 15 (13.9)                 | 4 (5.5)                       | NS      |

Note: Data are number of cases (percentage) or mean ± SD.
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV_{1}, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; NS, not significant; SD, standard deviation; VC, vital capacity.

Table 2 Blood biochemistry and estimated glomerular filtration rates

|                      | COPD patient group (n=108) | Non-COPD patient group (n=73) | P-value* |
|----------------------|---------------------------|-------------------------------|---------|
| Hb (g/dL)            | 13.2±1.9                  | 13.3±1.5                      | NS      |
| BUN (mg/dL)          | 17.0±6.9                  | 14.6±3.9                      | 0.0062  |
| Cr (mg/dL)           | 0.8±0.3                   | 0.7±0.1                      | <0.0001 |
| Cys (mg/L)           | 1.2±0.4                   | 0.9±0.2                      | <0.0001 |
| eGFR_{Cr} (mL/min/1.73m²) | 73.3±25.3              | 79.7±15.5                     | NS      |
| eGFR_{Cys} (mL/min/1.73m²) | 60.0±19.4                | 74.0±13.5                     | <0.0001 |
| BNP (pg/mL)          | 47.6 (39.0–58.0)          | 27.2 (21.5–34.4)              | 0.0004  |

Notes: Data are mean ± SD or geometric mean (95% CI). *Unpaired t-test.
Abbreviations: BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CI, confidence interval; COPD, chronic obstructive pulmonary disease; Cr, creatinine; Cys, cystatin C; eGFR_{Cr}, estimated glomerular filtration rate based on Cr; eGFR_{Cys}, estimated glomerular filtration rate based on Cys; Hb, hemoglobin; NS, not significant; SD, standard deviation.
with eGFR_{Cys}, but a higher prevalence of 53% was obtained when eGFR_{Cys} was used. Thus, the present results support the utility of eGFR_{Cys} over eGFR_{Cr}, as an index of early reduction in renal function.

Incalzi et al.\textsuperscript{14} pointed out the possibility that many COPD patients suffer from concealed CRF, with Cr levels, and thus eGFR_{Cr}, remaining at normal levels. This can occur because, although the capacity of the kidneys to remove Cr is impaired, the patient’s reduced muscle mass results in a lower Cr production rate. They also reported that the prevalence of CRF was higher in the COPD group when elderly COPD patients aged 65 years or more were compared with age-matched outpatients as the control group. In their report, the prevalence of CRF in the COPD group was 43% when concealed CRF and overt CRF were combined, and was significantly higher than the prevalence in the control group (23.4%). In our results, when evaluated with eGFR_{Cys}, the CKD prevalence in the COPD group was 31%, which was lower than the 43% figure reported by Incalzi et al but when evaluated with eGFR_{Cys}, our prevalence rose to 53%, which was higher than that of the aforementioned study. Because BMI in the COPD patients examined by Incalzi et al (mean BMI: 27.4 kg/m\textsuperscript{2}) was far higher than that in our patients (mean BMI: 21.1 kg/m\textsuperscript{2}), it is possible that this difference in BMI contributed to the difference in prevalence. Given that the prevalence of CKD also increased from 8% to 15% in the non-COPD group when eGFR_{Cys} instead of eGFR_{Cr} was used in our study, it may be more accurate to use the estimation formula based on Cys when reduced renal function is evaluated in elderly Japanese patients with reduced skeletal muscle mass.

Because a greater proportion of elderly COPD patients have a lower BMI in Japan compared to that in the West, the presence of CKD may be underestimated if evaluation is based on Cr only, which is dependent on muscle mass. We thus consider it more appropriate to evaluate eGFR based on both Cr and Cys levels. It has been reported that the Cys is not affected by the skeletal muscle volume, but by the somatic fat volume. It has also been identified that adipocytes may secrete Cys, although the underlying molecular mechanism is still unclear. Therefore, the Cys and eGFR_{Cys}, may be affected by adiposity and overestimated in obese individuals with an extremely high BMI,\textsuperscript{21} and use of Cys for the evaluation of CKD in COPD patients may not be adequate in Western countries where obese patients are seen at a high frequency.

The diagnosis of CKD in COPD patients may be useful in several ways. For example, CKD is a risk factor for the development of CVD, a representative comorbidity of COPD, and the presence of CKD may be related to the prognosis of COPD patients.

In recent years, Cys has been regarded as an index of arteriosclerosis, and it has been reported that Cys levels correlate with the development of cardiovascular events and patient life expectancy as a factor independent of CKD.\textsuperscript{27–33} Kiyosue et al.\textsuperscript{11} studied patients who underwent coronary angiography and reported that severe coronary artery disease might be present in patients who were considered to be at low risk based on an eGFR calculated from serum Cr, but who had a high Cys level; they concluded that Cys is useful as a marker for the severity of coronary artery disease as well as a marker for CKD.

Furthermore, CKD may be partially involved in the mechanism of anemia, a comorbidity of COPD, via impaired erythropoietin production. CKD is known to result in impaired metabolism of bone and minerals, which may be correlated with osteoporosis in COPD patients.

### Table 3 Prevalence of CKD in the COPD patient group and the non-COPD patient group

| COPD patient group (n=108) | Non-COPD patient group (n=73) | P-value$^a$ | OR $\pm 95\%$ CI |
|---------------------------|-------------------------------|------------|-----------------|
| eGFR_{Cr} < 60            | 33 (31)                       | 6 (8)      | 0.0004          | 4.91 (1.94–12.46) |
| eGFR_{Cys} < 60           | 57 (53)                       | 11 (15)    | <0.0001         | 6.30 (2.99–13.26) |

$^a$Notes: Data are number of cases (percentage), n=108. $^a$Cochran–Armitage trend test.

Abbreviations: CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR_{Cr}, estimated glomerular filtration rate based on Cr (mL/min/1.73 m\textsuperscript{2}); eGFR_{Cys}, estimated glomerular filtration rate based on Cys (mL/min/1.73 m\textsuperscript{2}); OR, odds ratio.

### Table 4 Prevalence of CKD by GOLD classification

| GOLD grade (n) | eGFR_{Cr} < 60 | eGFR_{Cys} < 60 |
|----------------|----------------|-----------------|
| 1 (10)         | 4 (40)         | 6 (60)          |
| 2 (37)         | 11 (29.7)      | 16 (43.2)       |
| 3 (27)         | 9 (33.3)       | 15 (55.6)       |
| 4 (34)         | 9 (26.5)       | 20 (58.8)       |
| P-value$^a$    | 0.531          | 0.421           |

$^a$Notes: Data are number of cases (percentage), n=108. $^a$Cochran–Armitage trend test.

Abbreviations: CKD, chronic kidney disease; eGFR_{Cr}, estimated glomerular filtration rate based on Cr (mL/min/1.73 m\textsuperscript{2}); eGFR_{Cys}, estimated glomerular filtration rate based on Cys (mL/min/1.73 m\textsuperscript{2}); GOLD, Global Initiative for Chronic Obstructive Lung Disease.
A limitation of this study is that CKD was diagnosed based on eGFR calculated from serum Cr and serum Cys levels without an assessment of microalbuminuria or other parameters. We could not perform urine testing for microalbuminuria in all the patients for reasons related to insurance coverage. The morbidity of CKD might have increased if we had performed microalbuminuria measurement in all the patients. Age, BMI, and smoking history were not matched between COPD and non-COPD groups, although these factors may have an impact on the GFR. Moreover, the subjects included only outpatients at our hospital and the study was based on a single medical institution. It is possible that age and severity were biased due to the small number of subjects; it is therefore desirable that the prevalence of CKD as a comorbidity of COPD be investigated further in a multicenter study.

The results of this study indicate that CKD is a comorbidity that occurs at a high rate in COPD patients; it is important that the presence of CKD should not be missed because CKD may influence the treatment and prognosis of patients. It is possible that the prevalence of CKD will be underestimated if Japanese COPD patients are diagnosed based only on serum Cr levels, considering that most of these patients are of advanced age and have reduced skeletal muscle mass and low BMI. Thus, it is considered more appropriate to evaluate CKD based on serum Cys levels in Japanese COPD patients.

**Author contributions**

All authors contributed to the study design, collection and interpretation of data, preparation of manuscript drafts, and approved the final version of the manuscript to be published.

**Disclosure**

The authors report no conflict of interest in this study.

**References**

1. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. *Eur Respir J*. 2003;21(2):347–360.
2. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. *Eur Respir J*. 2009;33(5):1165–1185.
3. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. *Chest*. 2005;128(4):2099–2107.
4. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. *Eur Respir J*. 2008;32(4):962–969.
5. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. *Eur Respir J*. 2006;28(6):1245–1257.
6. Global Initiative for Chronic Obstructive Lung Disease. *Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2010*. Global Initiative for Chronic Obstructive Lung Disease, Inc.; 2010. [cited April 1, 2011]. Available from: http://www.goldcopd.org/uploads/users/files/GOLDRreport_April112011.pdf. Accessed April 1, 2011.
7. Cooper RG. Effect of tobacco smoking on renal function. *Indian J Med Res*. 2006;124(3):261–268.
8. McAlister FA, Ezekwizot J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. *Circulation*. 2004;109(8):1004–1009.
9. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med*. 2004;351(13):1296–1305.
10. Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. *J Am Coll Cardiol*. 2003;41(1):47–55.
11. van Gestel YR, Chonchol M, Hoeks SE, et al. Association between chronic obstructive pulmonary disease and chronic kidney disease in vascular surgery patients. *Nephrol Dial Transplant*. 2009;24(9):2763–2767.
12. Terrazano C, Conti V, Di Stefano F, et al. Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. *Lung*. 2010;188(4):321–329.
13. Casanova C, de Torres JP, Navarro J, et al. Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2010;182(8):1004–1010.
14. Incalzi RA, Corsonello A, Pedone C, et al. Chronic renal failure: a neglected comorbidity of COPD. *Chest*. 2010;137(4):831–837.
15. Chandra D, Stamm JA, Palevsky PM, et al. The relationship between pulmonary emphysema and kidney function in smokers. *Chest*. 2012;142(3):655–662.
16. Corsonello A, Antonelli Incalzi R, Pistelli R, Pedone C, Bustacchini S, Lattanzio F. Comorbidities of chronic obstructive pulmonary disease. *Curr Opin Pulm Med*. 2011;17 Suppl 1:S21–S28.
17. Hojs R, Bevc S, Antoline B, Gorenjak M, Puklavcic L. Serum cystatin C as an endogenous marker of renal function in the elderly. *Int J Clin Pharmacol Res*. 2004;24(2–3):49–54.
18. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. *Am J Kidney Dis*. 2000;36(1):29–34.
19. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. *Am J Kidney Dis*. 2002;40(2):221–226.
20. Yashiro M, Kamata T, Segawa H, Kadoya Y, Murakami T, Muso E. Comparisons of cystatin C with creatinine for evaluation of renal function in chronic kidney disease. *Clin Exp Nephrol*. 2009;13(6):598–604.
21. Hojs R, Bevc S, Ekar R, Gorenjak M, Puklavcic L. Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function. *Nephrol Dial Transplant*. 2006;21(7):1855–1862.
22. Hojs R, Bevc S, Ekar R, Gorenjak M, Puklavcic L. Serum-cystatin C-based formulas for prediction of glomerular filtration rate in patients with chronic kidney disease. *Nephron Clin Pract*. 2010;114(2):c118–c126.
23. Vuppururi S, Fox CS, Coresh J, Woodward M, Muntner P. Differential estimation of CKD using creatinine- versus cystatin C-based estimating equations by category of body mass index. *Am J Kidney Dis*. 2009;53(6):993–1001.
24. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. *Am J Kidney Dis*. 2009;53(6):982–992.
25. Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S; Collaborators Developing the Japanese Equation for Estimated GFR. GFR estimation using standardized serum cystatin C in Japan. *Am J Kidney Dis*. 2013;61(2):197–203.
26. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. *Kidney Int*. 2011;80(1):17–28.
27. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. *Circulation*. 2007;116(1):85–97.
28. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. *Clin Chem*. 2005;51(2):321–327.
29. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. *Ann Intern Med*. 2006;145(4):237–246.
30. Lee M, Saver JL, Huang WH, Chow J, Chang KH, Ovbiagele B. Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis. *Circ Cardiovasc Qual Outcomes*. 2010;3(6):675–683.
31. Kiyosue A, Hirata Y, Ando J, et al. Plasma cystatin C concentration reflects the severity of coronary artery disease in patients without chronic kidney disease. *Circ J*. 2010;74(11):2441–2447.
32. Peralta CA, Katz R, Sarnak MJ, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. *J Am Soc Nephrol*. 2011;22(1):147–155.
33. Damman K, van der Harst P, Smilde TD, et al. Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure. *Heart*. 2012;98(4):319–324.